Ex-NJ Pharma Execs Admit To Generic Drug Price-Fixing Plot

Law360, New York (January 10, 2017, 2:13 PM EST) -- Two former Heritage Pharmaceuticals Inc. executives admitted Monday in Pennsylvania federal court to plotting to fix prices of antibiotics and diabetes treatments, marking the first charges in the U.S. Department of Justice's ongoing antitrust investigation into the generic drug industry.

Former Heritage CEO Jeffrey Glazer and Jason Malek, the company’s former president, each pled guilty to two-count felony charges that they conspired to manipulate prices and divvy up customers for doxycycline hyclate, an antibiotic, and glyburide, a medicine used to treat diabetes, according to court records....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.